EYPT
EyePoint Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$12.66-4.81%
Price as of Jul 20, 2026
EYPT financials
EyePoint Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M |
| Cost of revenue | $2.1M | $3.7M | $4.6M | $8.3M |
| Gross profit | $29.3M | $39.6M | $41.4M | $33.1M |
| Operating expenses | $272.7M | $185.4M | $116.5M | $132.7M |
| Operating income | -$243.4M | -$145.9M | -$75.1M | -$99.6M |
| Net income | -$232.0M | -$130.9M | -$70.8M | -$102.3M |
| EBITDA | -$229.3M | -$129.2M | -$69.0M | -$96.6M |
| Basic EPS | $-3.17 | $-2.32 | $-1.82 | $-2.74 |
| Diluted EPS | $-3.17 | $-2.32 | $-1.82 | $-2.74 |
| Balance sheet | ||||
| Cash & equivalents | $101.8M | $99.7M | $281.3M | $95.6M |
| Total assets | $364.0M | $418.5M | $355.2M | $180.4M |
| Total liabilities | $57.9M | $82.0M | $88.9M | $84.0M |
| Stockholders’ equity | $306.1M | $336.5M | $266.3M | $96.4M |
| Total debt | $22.8M | $21.9M | $4.9M | $46.3M |
| Net debt | -$79.0M | -$77.8M | -$276.4M | -$49.3M |
| Cash flow | ||||
| Operating cash flow | -$240.1M | -$126.2M | $1.9M | -$65.0M |
| Capital expenditure | -$3.3M | -$4.1M | -$3.5M | -$2.1M |
| Free cash flow | -$243.4M | -$130.3M | -$1.6M | -$67.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | -$295.0K |